北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月19日，万孚生物发布公告称，2025年上半年实现营业 收入12.46亿元，同比下降20.92%；归属于上市公司股东的净利润为1.89亿元，同比下降46.82%；归属 于上市公司股东的扣除非经常性损益的净利润1.54亿元，同比下降52.73%。 ...

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, with revenue at 1.246 billion yuan, down 20.92% year-on-year, and net profit at 189 million yuan, down 46.82% [1] - The in vitro diagnostic industry faced multiple challenges, including intensified competition and reduced demand, impacting the company's performance [1] Revenue Breakdown - In the infectious disease testing segment, the company generated revenue of 379.35 million yuan, a decrease of 21.14% compared to the same period last year, attributed to lower demand for respiratory disease testing in hospitals [1] - In the chronic disease management testing segment, revenue was 563.34 million yuan, down 26.06% year-on-year, influenced by industry policy adjustments leading to reduced testing volumes and prices [2] Product Development and Innovation - The company completed the development of the FG-3000 immunochromatography analyzer, enhancing digital and intelligent solutions for colloidal gold platform testing [2] - The company launched the LA-6000 laboratory intelligent assembly line based on the FC-9000 series, expanding its terminal coverage in the chemiluminescence field [3] - The company received regulatory approval for its MSI testing kit, marking a significant innovation in the detection technology [3] R&D and Regulatory Achievements - The company invested 206.25 million yuan in R&D, obtaining 11 authorized invention patents and 22 product registration certificates during the reporting period [4] - A total of 95 new products were launched, including 93 reagent projects and 2 instruments [4]

Core Viewpoint - Wanfu Biological (300482) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in the in vitro diagnostic sector [1] Financial Performance - The company achieved a revenue of 1.246 billion yuan in the first half of 2025, representing a year-on-year decrease of 20.92% [1] - The net profit attributable to shareholders was 189 million yuan, down 46.82% compared to the same period last year [1] Business Focus - Wanfu Biological primarily operates in the medical device sector, specifically in the field of in vitro diagnostics, focusing on the research, development, production, and marketing of rapid diagnostic reagents and supporting instruments [1]

格隆汇8月19日丨万孚生物(300482.SZ)公布半年度报告，2025年上半年，公司实现营业总收入 124,565.44万元，较上年同期下降20.92%；归属于上市公司股东的净利润18,919.89万元，较上年同期下 降46.82%；归属于上市公司股东的扣除非经常性损益后的净利润15,354.79万元，较上年同期下降 52.73%。 ...

Core Viewpoint - Wanfu Biological (300482.SZ) announced the termination of an investment project aimed at establishing Hainan Anhui Technology Co., Ltd. in collaboration with its affiliate Hainan Zhongmei Enterprise Management Co., Ltd. This decision is part of the company's strategy to focus on its core business and optimize resource allocation [1] Investment Project Details - The total investment for the project was estimated at 22.5 million yuan, with Wanfu Biological's wholly-owned subsidiary Hainan Wanxin Industrial Development Co., Ltd. planning to invest 6.75 million yuan (30% share) and Hainan Zhongmei intending to invest 15.75 million yuan (70% share) [1] Strategic Considerations - The company emphasized the importance of aligning its strategic execution with business development pace, aiming for a more robust and sustainable growth trajectory by concentrating on its core business areas and improving resource allocation efficiency [1]

Group 1 - The core point of the article is that Wanfu Biotech announced the convening of its fifth board meeting to discuss the confirmation and increase of related party transactions for the first half of 2025 [2] - In 2024, the revenue composition of Wanfu Biotech is reported to be 97.59% from diagnostic products and 2.41% from other sources [2]

万孚生物（SZ 300482，收盘价：24.8元）8月19日晚间发布半年度业绩报告称，2025年上半年营业收入 约12.46亿元，同比减少20.92%；归属于上市公司股东的净利润约1.89亿元，同比减少46.82%；基本每 股收益0.39元，同比减少50%。 （文章来源：每日经济新闻） ...

智通财经APP讯，万孚生物(300482.SZ)发布2025年半年度报告，该公司营业收入为12.46亿元，同比减 少20.92%。归属于上市公司股东的净利润为1.89亿元，同比减少46.82%。归属于上市公司股东的扣除非 经常性损益的净利润为1.54亿元，同比减少52.73%。基本每股收益为0.39元。 ...

证券代码：300482 证券简称：万孚生物 公告编号：2025-039 债券代码：123064 债券简称：万孚转债 广州万孚生物技术股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）第五届监事会第十次会议 于 2025 年 8 月 19 日下午 14:00 在公司会议室以现场与通讯相结合方式召开，会议 通知于 2025 年 8 月 10 日以邮件、电话的方式向全体监事发出。会议应到监事 3 名， 实到 3 名，会议召开符合《公司法》和《公司章程》规定。会议由公司监事彭雷清 女士主持。 经与会监事认真审议，本次会议审议并通过以下议案： 一、审议通过《关于<2025 年半年度报告及其摘要>的议案》 经核查，监事会认为：董事会编制和审核 2025 年半年度报告的程序符合法律、 行政法规以及中国证监会的有关规定，报告内容真实、准确、完整地反映了 公司 经营、管理及财务等各方面的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 三、审议通过《关于公司及控股子公司 2025 ...

华泰联合证券有限责任公司关于 广州万孚生物技术股份有限公司全资子公司终止与关联企 业共同投资暨关联交易的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作 为广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）2022 年度 创业板向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务管理办 法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关规定，对万孚生物全资 子公司终止与关联企业共同投资暨关联交易情况进行了核查，具体情况如下： 广州万孚生物技术股份有限公司（以下简称"公司"）于 2022 年 4 月 24 日 召开第四届董事会第十次会议，第四届监事会第七次会议审议通过了《关于全 资子公司与关联企业共同投资暨关联交易的议案》，同意公司的全资子公司海南 万信产业发展有限公司（下称"海南万信"）拟与公司的关联方海南众美企业管 理有限公司（下称"海南众美"）共同投资设立海南安汇科技有限公司。项目总 投资额预计 22,500 万元，其中海南万信拟出资 6,750 万元、出资比例为 30%， 海南众美拟 ...